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ABSTRACT 
 
Aims: Transcranial direct stimulation (tDCS) is recently discussed as a therapeutic option in 
psychiatric disorders and has brought preliminary convincing results in the treatment of depressive 
disorders. Hence the optimal stimulation parameters still remain elusive as randomized controlled 
trials over last years used divergent stimulation protocols and duration, frequency, and current 
strength still have to be standardized.  
Presentation of Cases: In this case series we report on the safety of twice daily 30 min tDCS at 2 
mA over longer stimulation periods and interval treatment. Six patients (mean age 59.5±22.3, age 
range 29-87 years) with major depressive disorder received 20 to 31 tDCS treatments within 14 and 
50 days, including acute treatment series and maintenance treatment. In the majority of participants, 
tDCS exerted antidepressant effects. tDCS was well tolerated and there were no clinically relevant 
adverse events.  
Discussion: These preliminary data suggest safety and tolerability of twice-daily 30 min tDCS even 
in a prolonged protocol. 
Conclusion: tDCS is gaining growing importance as a therapeutic tool in neuropsychiatric disorders 
and seems to be safe even when applied extensively. 
Case Study 
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1. INTRODUCTION 
 
Transcranial direct current stimulation (tDCS) is 
being applied for the treatment of psychiatric 
disorders since a decade and has shown positive 
results in various disorders, i.e. in depressive 
disorders and to some extent in schizophrenia 
[1]. While early tDCS studies used in the clinical 
context applied 1 mA current strength and 15 min 
duration, recent studies showed that 2 mA and 
2x20 min duration per day were safe [2,3]. The 
largest study up to now, the SELECT-TDCS trial 
by Brunoni et al. [4] used 10 treatments of 30 min 
within two weeks, followed by two maintenance 
treatments. In this large trial of 120 participants, 
no adverse events were observed. Recently, a 
study in patients with severe depression showed 
that twice-daily 30 min duration and 2 mA current 
strength were safely applied within 5 days of 
intervention [5]. Given a supposed dosage-
related effect of tDCS, enhanced and prolonged 
stimulation protocols have to be evaluated. 
 
Here, we report data on safety and tolerability of 
twice-daily 30 min and 2 mA tDCS in six patients 
who were treated with tDCS as an adjunct to 
psychopharmacotherapy in major depressive 
disorder. These patients received between 20 
and 31 stimulations during acute and 
maintenance treatment, reaching from two up to 
seven weeks. 
 
2. PRESENTATION OF CASES 
 
The cases presented here are pilot patients prior 
to the beginning of a clinical trial for the treatment 
of major depressive disorders with a combined 
regimen of citalopram/escitaloprame and twice 
daily tDCS with a total number of 20 to 30 tDCS 
sessions. This so-called AzteK study 
(“Antidepressivum und zusätzliche transkranielle 
elektrische Kortexstimulation” – antidepressant 
and additional transcranial electrical cortex 
stimulation) was approved by the local          
ethics committee and was registered                   
at the World Health Organization International 
Clinical Trials Registry Platform 
(http://apps.who.int/trialsearch/Trial2.aspx?TrialI
D=DRKS00008009) 
 
All patients gave written and oral informed 
consent for an individual treatment with tDCS as 
an add-on to present medication in order to 
evaluate feasibility and tolerability of the tDCS 
protocol of the upcoming clinical trial. tDCS was 
applied with an Eldith DC-stimulator (neuroConn, 
Ilmenau, Germany). Saline-soaked sponge 
electrodes (35 cm
2
) were positioned over the left 
and right dorsolateral prefrontal cortex (F3: 
Anode; F4: Cathode) as previously reported [4]. 
2 mA tDCS was applied twice for 30 min within a 
3 h interval in the morning. Clinical changes were 
measured with Clinical Global Impression (CGI), 
daily activities were measured with Global 
Assessment of Functioning (GAF). 
 
2.1 Patient 1 
 
The 29 year old patient was suffering from 
recurrent depressive episodes since he was 16 
years old. Intermittent pharmacotherapy had no 
effect (venlafaxine) or had severe side effects 
(mirtazapine, bupropion). Upon admission, he 
presented a depressive syndrome for two 
months after discontinuing duloxetine four 
months before due to erectile dysfunction. The 
patient decided to restart duloxetine 90 mg in 
combination with 15 sessions of tDCS within 16 
days. He showed a clear improvement of 
rumination, anhedonia, impetus, sleep and mood 
after two weeks. However, after discontinuing 
tDCS, he showed a severe relapse of depressive 
symptoms. Medication change to citalopram 40 
mg showed no improvement and decision for a 
second tDCS series was made two weeks after 
end of first series. After 10 stimulations within 5 
days the patient showed clear improvement of 
depressive symptoms and tDCS was 
discontinued. The patient only reported moderate 
side effects consisting in mild headache for a few 
hours after the first three tDCS sessions. GAF 
was 25 at admission, CGI 6. At discharge, GAF 
was 47 and CGI 4. 
 
2.2 Patient 2 
 
The 70 year old patient was suffering from a 
recurrent depressive disorders over 1 ½ years 
and was treated as an inpatient for one year 
including several antidepressant and 
augmentative regimen changes, a series of 20 
acute treatments with electroconvulsive therapy 
(ECT) including maintenance ECT over weeks. 
Overall, treatment strategies including ECT 
series only exerted moderate and transient 
improvement, and the patient was transferred to 
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our service for tDCS. She presented a severe 
lack of impetus, depressed mood, anxiety, inner 
tension and akathisia. 20 tDCS treatments were 
applied within 14 days as an add-on to stable 
pharmacologic treatment, consisting in 
mocobemide, opipramol, and risperidone. The 
patient only showed modest improvement, 
however there was a light decline in inner tension 
and akathisia. Side effects of tDCS did not occur. 
GAF (25) and CGI (6) did not change during 
inpatient stay. 
 
2.3 Patient 3 
 
The 59 year old patient was suffering from a 
chronic depression over several years, 
presenting with sadness, senselessness of life, 
lack of impetus, and anhedonia. Over the past 
years, he was treated with St. John’s wort, 
DHEA, testosterone, 5-HTP, and thyroxin. 
Medical history comprised no relevant somatic 
disorder. Admission followed the appearance of 
suicidal thoughts. Due to his concerns about a 
psychopharmacologic regimen, a series of 31 
tDCS within 29 days was performed. Suicidal 
thoughts vanished, mood and impetus improved 
markedly, and the patient was able to maintain 
structure of daily activities as an outpatient and 
to restart working. Side effects comprised only 
mild tingling and itching sensation under the 
electrodes. GAF improved from 45 to 55, CGI 
from 5 to 4. 
 
2.4 Patient 4 
 
The 32 year old patient was suffering from 
recurrent depressive episodes since she was 16. 
Psychiatric history comprised two inpatient stays 
in the last 4 years, including several treatment 
regimen changes and a series of ECT. Upon 
actual submission, she presented a severe 
depressive syndrome since 4 months, although 
continuing her medication of venlafaxine, 
quetiapine, and lithium at stable doses. She 
preferred to continue her medication and agreed 
in a series of 30 tDCS within 21 days. She 
showed clear improvement of mood, impetus, 
anhedonia, and rumination. tDCS was tolerated 
without any side effect. CGI improved from 5 to 4 
during hospital stay, GAF from 35 to 45. 
 
2.5 Patient 5 
 
The 50 year old patient was suffering from 
recurrent depressive episodes for 31 years. In 
her past medical history she was diagnosed with 
double depression and was treated with 
venlafaxine, quetiapine, buspirone, and 
zolpidem. Furthermore she received 
lisdexamfetamine for an attention deficit 
syndrome. Upon actual admission due to a 
depressive syndrome with suicidal thoughts, 
venlafaxine, buspirone, and lisdexamfetamine 
were replaced by tranylcypromine and 
amisulpride without improvement. Decision for 
ECT was set and the patient received a series of 
12 bilateral ECT, followed by maintenance ECT 
for several weeks. Pharmacotherapy with 
tranylcypromine, quetiapine, and amisulpride 
was continued and the patient showed a clinical 
response after ECT. However, due to cognitive 
deterioration, maintenance ECT had to be 
stopped and a series of 10 tDCS was performed, 
followed by 12 maintenance tDCS over 6 weeks 
in an outpatient setting. During acute and 
maintenance tDCS, clinical improvement by ECT 
carried on. Except for light skin reddening, the 
patient reported no side effects. GAF improved 
from 45 to 65 and CGI from 6 to 3 during hospital 
and outpatient treatment. 
 
2.6 Patient 6 
 
The 87 year old patient was suffering from 
recurrent depressive episodes since four years 
with the leading symptom of nausea. During 
several inpatient stays over the past years, a 
variety of antidepressants, antipsychotics, 
anxiolytics, and hypnotics only had modest and 
transient effects on depressive symptoms. Upon 
admission, he presented with nausea, vertigo, 
depressed mood, and lack of impetus. Actual 
pharmacotherapy of moclobemide, mirtazapine, 
and aripiprazole was continued and the patient 
received 20 tDCS during inpatient stay and 
further 10 maintenance tDCS during over a 5 
week outpatient stay. Nausea vanished 
completely during acute tDCS treatment, 
depressive symptoms improved and the patient 
remained stable during outpatient treatment. 
tDCS treatment showed no side effects. GAF 
increased from 35 to 55 during tDCS, CGI sank 
from 5 to 4. 
 
3. DISCUSSION 
 
In this case series with 6 patients (mean age 
59.5±22.3, age range 29-87 years) we aimed at 
evaluating the safety and tolerability of repeated 
twice-daily tDCS under naturalistic conditions. 
Although this case series is limited due to 
heterogeneity of patient characteristics, 
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concomitant medication, treatment resistance 
and different treatment protocols (total number of 
tDCS and treatment intervals), it shows that 
twice-daily tDCS can be safely applied over 
longer treatment periods and that side effects are 
mild and transient, and do not exceed the side 
effects reported in previous studies, even when 
stimulating with enhanced protocols. Even in 
older patients, intensive tDCS was well tolerated 
without any adverse effects, as also previously 
reported [6]. tDCS treatment in higher dosage 
and increased total number of stimulations 
exerted promising effects in this mainly treatment 
resistant or chronically depressed patient 
sample. As there is growing evidence that tDCS 
has a dosage-dependent effect, i.e. in depressive 
disorders, there is a need for optimizing 
stimulation protocols in terms of amperage, 
duration, intervals between stimulations and total 
treatment duration. 
 
4. CONCLUSION 
 
tDCS has proven to be safe tool for 
neuromodulation and is currently evaluated in a 
variety of neuropsychiatric disorders. Over the 
past years, stimulation protocols were currently 
expanded in length and strength of application. It 
is likely that enhanced protocols are more 
effective without increasing the risk of adverse 
effects. There is a need for systematic 
investigation of new stimulation protocols. 
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